A 4-miRNA signature predicts the therapeutic outcome of glioblastoma
暂无分享,去创建一个
C. Belka | H. Zitzelsberger | C. Rödel | A. Pitea | K. Unger | K. Lauber | C. Sticht | J. Steinbach | M. Niyazi | U. Ganswindt | M. Mittelbronn | F. Zehentmayr | D. Piehlmaier
[1] Ming-yang Li,et al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients , 2015, Oncotarget.
[2] Zeyou Wang,et al. MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ. , 2015, Biochemical and biophysical research communications.
[3] Karl T Kelsey,et al. Integrative Analysis of Micro‐RNA, Gene Expression, and Survival of Glioblastoma Multiforme , 2015, Genetic epidemiology.
[4] C. Belka,et al. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients , 2014, Radiation oncology.
[5] R. Vyzula,et al. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. , 2014, Carcinogenesis.
[6] J. Shou,et al. Identification of dysregulated miRNAs and their regulatory signature in glioma patients using the partial least squares method , 2014, Experimental and therapeutic medicine.
[7] S. Volinia,et al. A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas , 2014, PloS one.
[8] C. Sarkar,et al. Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing , 2014, BMC Genomics.
[9] Xiaoning Peng,et al. An Integrated mRNA and microRNA Expression Signature for Glioblastoma Multiforme Prognosis , 2014, PloS one.
[10] Y. Kondo,et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma , 2014, Oncogene.
[11] Thomas Welzel,et al. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? , 2014, Radiation oncology.
[12] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[13] J. Tonn,et al. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option , 2014, Journal of Neuro-Oncology.
[14] Kaiming Gao,et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma , 2014, Journal of experimental & clinical cancer research : CR.
[15] Amaia Agirre,et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. , 2014, Neuro-oncology.
[16] Konstantin Nikolaou,et al. Visualization, imaging and new preclinical diagnostics in radiation oncology , 2014, Radiation oncology.
[17] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[18] Z. Wang,et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type , 2013, Journal of experimental & clinical cancer research : CR.
[19] M. Delorenzi,et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.
[20] H. Kim,et al. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity , 2012, Radiation oncology.
[21] J. Tonn,et al. MiRNA expression patterns predict survival in glioblastoma , 2011, Radiation oncology.
[22] T. Cloughesy,et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme , 2011, Advances in therapy.
[23] W. Krzyzosiak,et al. Practical Aspects of microRNA Target Prediction , 2011, Current molecular medicine.
[24] P. Gutin,et al. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches , 2011, Radiation oncology.
[25] E. Chiocca,et al. Potential role of miRNAs and their inhibitors in glioma treatment , 2010, Expert review of anticancer therapy.
[26] Keiji Suzuki,et al. miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. , 2010, Cancer letters.
[27] A. Gulino,et al. MicroRNAs as biomarkers for CNS cancer and other disorders , 2010, Brain Research.
[28] Kai Stühler,et al. Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas , 2010, Brain pathology.
[29] Wei Zhu,et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. , 2010, Oncology reports.
[30] Sun-Mi Park,et al. The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.
[31] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[32] J. Mehrkens,et al. Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas , 2009, Journal of neuropathology and experimental neurology.
[33] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[34] V. Kim,et al. Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.
[35] Francesco Tomasello,et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors , 2009, Journal of Neuro-Oncology.
[36] Jaewoo Kang,et al. Robust Likelihood-Based Survival Modeling with Microarray Data , 2009 .
[37] G. Reifenberger,et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.
[38] Margaret Wrensch,et al. Epidemiology of brain tumors. , 2007, Neurologic clinics.
[39] Kazuhiko Hayashi,et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.
[40] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[41] G. Maira,et al. Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.
[42] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[43] Teng Chen,et al. Downregulation of microRNA-124 predicts poor prognosis in glioma patients , 2014, Neurological Sciences.
[44] J. Tonn,et al. Therapeutic options for recurrent malignant glioma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] M. Campone,et al. [Prognostic and predictive factors for gliomas in adults]. , 2009, Bulletin du cancer.
[46] M. Wolter,et al. MicroRNA: Biogenesis, Regulation, and Role in Primary Brain Tumors , 2009 .
[47] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .